No Data
Special Treat Meigu (000615.SZ): A net loss of 41.1791 million yuan in the first quarter.
On April 29th, Glorious Exchange reported that ST Meigu (000615.SZ) released the first quarter report for 2025. During the reporting period, revenue was 0.238 billion yuan, a year-on-year decrease of 13.49%; the net income attributable to shareholders of the listed company was -41.1791 million yuan, the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -37.2647 million yuan, and the EPS was -0.054 yuan.
ST Mitani: 2024 Annual Report
ST Mitani: 2024 Annual Report Summary
ST Mitani: Report for the first quarter of 2025
Jointown Pharmaceutical Group invested 0.673 billion to participate in the restructuring, planning to "take control" of Special Treat Meigu and increase investment in medical aesthetics?| Quick read of the announcement.
① Jointown Pharmaceutical Group plans to invest 0.673 billion yuan to participate in the restructuring of Aoyuan Meigu; ② In recent years, Jointown Pharmaceutical Group's medical aesthetics business has grown rapidly and has established partnerships with many domestic medical aesthetics giants, clearly indicating an intention to strengthen this sector.
Chinese Securities Regulator to Slap Aoyuan Beauty Valley Technology With 2 Million Yuan Fine Over Disclosure Violations
More Unpleasant Surprises Could Be In Store For Aoyuan Beauty Valley Technology Co.,Ltd.'s (SZSE:000615) Shares After Tumbling 26%
